Malignant pleural mesothelioma

Researchers are testing whether adding vitamin B12 to standard chemotherapy helps people with pleural mesothelioma that cannot be removed by surgery. The trial gives participants pemetrexed and cisplatin, two chemotherapy drugs that block tumor cell growth in different ways, alon…

This trial compares two treatments for people with advanced malignant pleural mesothelioma, a cancer of the lining of the lungs, that has progressed after initial chemotherapy. Half of the participants receive pembrolizumab, an immunotherapy that helps the immune system fight can…

This trial tests an experimental drug, RSO-021, given directly into the chest cavity of people with malignant pleural effusion—a buildup of fluid around the lungs caused by advanced solid tumors or mesothelioma. The study aims to find a safe dose and check for early signs that th…

This study tested whether adding the immunotherapy drug atezolizumab to standard treatment (bevacizumab plus chemotherapy) helps people with advanced malignant pleural mesothelioma live longer. The trial involved 400 adults whose cancer could not be removed by surgery. Researcher…

This early-phase trial is testing whether combining a precise type of radiation (SBRT) with immunotherapy can safely treat pleural mesothelioma, a rare cancer of the lung lining. About 20 adults with confirmed mesothelioma will receive both treatments. The main goal is to see if …

This study tested a new drug called PM8002, which targets two proteins that help cancer grow, combined with standard chemotherapy. It involved 31 adults with a rare cancer called malignant mesothelioma that could not be removed by surgery. The goal was to see if the combination s…

This early-phase trial tested whether giving the immunotherapy drug pembrolizumab (Keytruda) after radiation therapy is safe for people with malignant pleural mesothelioma, a rare cancer of the lung lining. Twenty-five participants received radiation followed by pembrolizumab. Th…

This study tested a drug called pembrolizumab in 65 people with malignant mesothelioma, a rare cancer of the lining around the lungs or abdomen. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow the disease, but…

This phase 3 trial tested a new approach for malignant pleural mesothelioma, a rare and aggressive cancer of the lung lining. Researchers gave 53 patients a gene therapy (rAd-IFN) injected into the chest cavity, along with the drugs celecoxib and gemcitabine. The goal was to see …

This study looked at whether a short, intense course of chest radiation given just before surgery can kill cancer cells and prevent them from spreading outside the chest during the operation. It involved 104 people with malignant pleural mesothelioma, a cancer linked to asbestos.…

This study tested whether continuing chemotherapy with gemcitabine after initial treatment can help patients with diffuse pleural mesothelioma keep their cancer under control longer. 64 patients who responded to first-line chemo were randomly assigned to receive gemcitabine or no…

This pilot study tested whether adding intrapleural photodynamic therapy (PDT) to standard surgery and chemotherapy is safe and feasible for patients with malignant pleural mesothelioma. Six participants received a light-sensitive drug followed by laser light inside the chest cav…

This study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy for Chinese patients with advanced pleural mesothelioma, a rare cancer of the lung lining. 102 patients who could not have surgery were randomly a…

This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with advanced pleural mesothelioma live longer. The trial included 214 adults whose cancer could not be removed by surgery. Participants received either the combination or a s…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…

This phase II trial tested a drug called Bintrafusp alfa (M7824) in 47 people with advanced pleural mesothelioma that had worsened after platinum-based chemotherapy. The drug aims to block two proteins that help tumors grow. Researchers measured how long patients lived without th…

This study tested a new way to deliver chemotherapy directly to the tumor in adults with malignant pleural mesothelioma that cannot be removed by surgery. The treatment, called transarterial chemoperfusion, uses a combination of three drugs (cisplatin, methotrexate, and gemcitabi…

This early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19…

This study looks back at 204 patients with untreated, inoperable malignant pleural mesothelioma who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, through an early access program in France. Researchers will collect data from medical records to see ho…